Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Lawitz

Showing results (151-160 of 157) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 157 results.
Gastroenterology|August 9, 2013
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trialFred Poordad, Eric Lawitz, K Rajender Reddy, et al.
The Lancet. Gastroenterology & Hepatology|August 14, 2017
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trialsEric Lawitz, Maria Buti, John M Vierling, et al.
The Lancet. Infectious Diseases|March 19, 2013
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trialEric Lawitz, Jay P Lalezari, Tarek Hassanein, et al.
The New England Journal of Medicine|November 14, 2023
Efficacy and Safety of Elafibranor in Primary Biliary CholangitisKris V Kowdley, Christopher L Bowlus, Cynthia Levy, et al.
Gastroenterology|April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsIra M Jacobson, Eric Lawitz, Edward J Gane, et al.
Lancet (London, England)|December 10, 2019
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M Younossi, Vlad Ratziu, Rohit Loomba, et al.
The New England Journal of Medicine|November 18, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 InfectionGraham R Foster, Nezam Afdhal, Stuart K Roberts, et al.
Pageof 16

Showing results (151-160 of 157) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 157 results.
Gastroenterology|August 9, 2013
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trialFred Poordad, Eric Lawitz, K Rajender Reddy, et al.
The Lancet. Gastroenterology & Hepatology|August 14, 2017
Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trialsEric Lawitz, Maria Buti, John M Vierling, et al.
The Lancet. Infectious Diseases|March 19, 2013
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trialEric Lawitz, Jay P Lalezari, Tarek Hassanein, et al.
The New England Journal of Medicine|November 14, 2023
Efficacy and Safety of Elafibranor in Primary Biliary CholangitisKris V Kowdley, Christopher L Bowlus, Cynthia Levy, et al.
Gastroenterology|April 10, 2017
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized TrialsIra M Jacobson, Eric Lawitz, Edward J Gane, et al.
Lancet (London, England)|December 10, 2019
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialZobair M Younossi, Vlad Ratziu, Rohit Loomba, et al.
The New England Journal of Medicine|November 18, 2015
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 InfectionGraham R Foster, Nezam Afdhal, Stuart K Roberts, et al.
Pageof 16